Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade

Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers

“…Recent studies have shed light on the intricate dynamics of tumor cell dissemination and metastasis (27,28). Understanding these processes in greater detail offers opportunities for developing targeted interventions to disrupt critical steps in the metastatic cascade (29)(30)(31). By unraveling the complexities of tumor cell interactions with the microenvironment and genetic factors influencing metastasis, researchers aim to identify novel therapeutic approaches to combat metastatic cancers.…”

Deubiquitinase UCHL1 stabilizes KDM4B to augment VEGF signaling and confer bevacizumab resistance in clear cell renal cell carcinoma

“…A considerable portion of patients with ccRCC inevitably acquire recurrence and distant metastases after laparoscopic treatment [ 3 ]. The current strategies for this malignant carcinoma include targeted therapy, immunotherapy, and cytokine drugs [ 4 ]. However, patients with metastatic ccRCC still have an unfavorable prognosis overall, as indicated by a 5-year survival rate of only 10 % [ 5 ].…”

FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma

“…Renal cell carcinoma (RCC) is among the top 10 malignant neoplasms in men worldwide and encompasses a heterogeneous group of histological subtypes, including the most commonly diagnosed clear cell renal cell carcinoma (ccRCC) ( 1 , 2 ). In addition to nephrectomy, targeted therapies and immunotherapy have been developed to treat RCC ( 3 ). Nevertheless, the response is varied and poor, and most patients eventually develop metastases and drug resistance, with the median survival of patients remaining less than 3 years ( 3 ).…”

“…In addition to nephrectomy, targeted therapies and immunotherapy have been developed to treat RCC ( 3 ). Nevertheless, the response is varied and poor, and most patients eventually develop metastases and drug resistance, with the median survival of patients remaining less than 3 years ( 3 ).…”